{"doi":"10.2217/fon-2022-0519","title":"Experience with Second-Line Trabectedin in Daily Clinical Practice: Case Studies","abstract":null,"journal":"Future Oncology","year":2022,"id":595542,"datarank":0.24141568686511508,"base_score":1.6094379124341003,"endowment":1.6094379124341003,"self_citation_contribution":0.24141568686511508,"citation_network_contribution":0.0,"self_endowment_contribution":0.24141568686511508,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":4,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":260053,"name":"Nadia Hindi","orcid":"0000-0002-5864-762X","position":1,"is_corresponding":false},{"id":459668,"name":"Giovanni Grignani","orcid":"0000-0001-5515-569X","position":2,"is_corresponding":false},{"id":459674,"name":"Alessandra Merlini","orcid":"0000-0002-5280-1411","position":3,"is_corresponding":false},{"id":1525064,"name":"Tony Ibrahim","orcid":"0000-0001-9728-8554","position":4,"is_corresponding":false},{"id":621790,"name":"Axel Le Cesne","orcid":"0000-0002-8006-8659","position":5,"is_corresponding":false},{"id":260060,"name":"Javier Martín‐Broto","orcid":"0000-0001-7350-6916","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Experience with Second-Line Trabectedin in Daily Clinical Practice: Case Studies","abstract":"As a recommended second-line option for advanced soft tissue sarcoma, trabectedin can provide the necessary balance between long-term tumor control and preserved quality of life. Three case studies illustrate the long-lasting responses that patients can achieve with second-line trabectedin. A female patient with metastatic leiomyosarcoma maintained disease control for 2 years with trabectedin (× 41 cycles) with excellent tolerability and no relevant adverse events. At the time of writing, a male patient with a metastatic solitary fibrous tumor was asymptomatic after 30 cycles of trabectedin and treatment was ongoing. A young male patient with a recurrent, nonresectable, retroperitoneal myxoid/round cell liposarcoma was able to continue his sporting activities (triathlons) over 2 years with trabectedin (× 14 cycles) plus watchful waiting.","is_dataset_classified":null,"base_score":1.6094379124341003,"endowment":1.6094379124341003,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"36200932","pmcid":null,"openalex_id":"https://openalex.org/W4302425178","authors":[],"funders":[{"funder_name":"PharmaMar","grant_id":"","title":null},{"funder_name":"PharmaMar","grant_id":"","title":null}],"total_grants":2,"fwci":0.5944,"citation_percentile":0.68654045,"influential_citations":0,"citation_trend":[{"year":2022,"count":1},{"year":2023,"count":1},{"year":2024,"count":1},{"year":2025,"count":1}],"oa_status":"hybrid","license":"cc-by-nc-nd","oa_locations":[{"url":"https://doi.org/10.2217/fon-2022-0519","host_type":"journal"},{"url":"https://doi.org/10.2217/fon-2022-0519","host_type":"publisher"},{"url":"https://www.tandfonline.com/doi/pdf/10.2217/fon-2022-0519","host_type":"publisher"},{"url":"https://pubmed.ncbi.nlm.nih.gov/36200932","host_type":"repository"}],"fields_of_study":["Sarcoma Diagnosis and Treatment","Soft tissue tumor case studies","Cardiac tumors and thrombi","Humans","Male","Female","Adult","Trabectedin","Quality of Life","Antineoplastic Agents, Alkylating","Neoplasm Recurrence, Local","Sarcoma","Liposarcoma","Tetrahydroisoquinolines","Dioxoles"],"mesh_terms":["Trabectedin","Adult","Dioxoles","Female","Humans","Liposarcoma","Male","Neoplasm Recurrence, Local","Quality of Life","Sarcoma","Antineoplastic Agents, Alkylating","Tetrahydroisoquinolines"],"keywords":["Trabectedin","Medicine","Tolerability","Liposarcoma","Soft tissue sarcoma","Adverse effect","Asymptomatic","Oncology","Leiomyosarcoma","First line","Internal medicine","Myxoid liposarcoma","Sarcoma","Surgery","Soft tissue","Pathology","Solitary Fibrous Tumor","Growth Modulation Index","Advanced Leiomyosarcoma","Long Responder","Myxoid/round Cell Liposarcoma"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"},{"sdg_number":0,"sdg_label":"Quality Education"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-27T17:36:32.724877Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}